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Emergence of resistance after therapy with antibiotics used alone or
combined in a marine model
J. C. Pechere, B. Marchoa, M. MicWa-Hamzehpour and R. Auckentnaler
Departement de Microbiologie, Centre Midical Universitaire, 9 avenue de Champel,
1211 Geneve 4, Switzerland
A marine model of peritonitis allowing detection and quantification of in-vivo
acquired resistance during short term therapy has been used in order to evaluate the
capacity of antimicrobial combinations to limit emergence of resistance, as compared
to individual components of the regimens. Mice were challenged intraperitoneally with
10* cfu of bacteria. Two hours later, a single antibiotic dose was injected sub-
cutaneously: amikacin (15mg/kg), ceftriaxone (50mg/kg), pefloxacin (25 mg/kg),
amikacLn + ceftriaxone, amikacin + pefloxacin or ceftriaxone + pefloxacin.
Escherichia coli and Staphylococcus aureus never became resistant Single drug therapy
yielded resistant mutants in Enterobacter cloacae, Serratia marcescens, Klebsiella
pnewnoniae and Pseuaomonas aentginosa as follows: 74% of ceftriaxone-treated
animals, 57% of pefloxacin treated animals and 27% of amikacin treated animals. All
the tested combinations reduced the frequency of in-vivo acquired resistance produced
by single drugs, and no combination selected resistance when the separate agents of
the combination did not Combining antimicrobial agents limits the risk of emergence
of resistance during antibiotic therapy.
Introduction
Antibiotic combinations are commonly used in clinical practice. Too often, the pre-
scription of more than a single antimicrobial agent in a specific patient is not based upon
scientifically established facts, but rather reflects the insecurity felt by clinicians
confronted with life-threatening infections. However, in other cases, prognosis of severe
infectious diseases is improved by combined antimicrobial therapy. To a large extent,
the rationale of such therapy includes the wish to widen the antibacterial spectrum in
mixed infections or in critically ill patients before identification of the invading pathogens
or the desire to enhance antibacterial activity in some well-selected cases such as
deep-seated pseudomonal infections or enterococcal endocarditis. Other reasons for
using combinations have also been advocated, among them prevention of emergence of
resistance. This represents a legitimate reason for using multiple drug therapy in
tuberculosis, but in other bacterial infections it has been difficult so far to demonstrate
similar beneficial effects (Klastersky, 1984).
However, acquired resistance to broad-spectrum antibiotics during therapy is a
growing concern. The fact is well established with many of the newer ^-lactam
compounds (Sanders & Sanders, 1985) and the threat is genuine with the recently
developed fluoroquinolones which can easily produce resistant mutants in vitro (Chin
& Neu, 1983, 1984; Duckworth & Williams, 1984; Sanders et al., 1984).
In this laboratory, a murine model of peritonitis allowing detection and quantification
of in-vivo acquired resistance during short-term therapy has been used in order to
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evaluate the capacity of antimicrobial combinations to limit emergence of resistance,
compared with components of the regimens used alone.
Material and methods
Antibiotics and strains. Ceftriaxone (Roche, Basel, Switzerland), pefloxacin (Rhone-
Poulenc, Paris, France) and amikacin (Bristol-Myers, Cham, Switzerland) have been
kindly provided in form of powders of known potency, which were dissolved in
phosphate-buffered saline. The nine strains used in the study were clinical isolates, as
listed in Table I. They were maintained in skimmed milk and stored at —70°. Before
study they were thawed and grown in L. broth.
Animal model. Swiss Webster female mice, weighing 20-30 g were used. Experimental
peritonitis was established by intraperitoneal injection of 1 ml of a mixture containing
108 cfu of a pure culture and 125 mgof sterilized talcum in NaCl solution 0-9%. Bacterial
suspensions were prepared from 24-h cultures in L. broth. Two hours after challenge,
the antimicrobial treatment was administered subcutaneously as a single dose in 0-2 ml,
of 0-9% NaCl. The following dosage regimens were used: amikacin 15 mg/kg, ceftriaxone
50 mg/kg, pefloxacin 25 mg/kg, amikacin 15 mg/kg + ceftriaxone 50 mg/kg, amikacin
15 mg/kg -(- pefloxacin 25 mg/kg, ceftriaxone 50 mg/kg + pefloxacin 25 mg/kg. Twenty-
four hours after challenge, animals were sacrificed by hyperanaesthesia. Peritoneal
secretions were sampled through a 2-3 mm left iliac incision. Ten microlitres of peri-
toneal secretions were plated on L. agar for colony counting after appropriate dilutions,
while the rest of the sample was placed into L. broth for further identification and
bacterial population analysis.
Bacterial populations analysis was performed only on micro-organisms with the same
identity (API system) as the strain originally inoculated. The peritoneal exudates grown
in L. broth, after determination of the cfu, were diluted in order to provide 10* cfu (100 /*1
plated on L. agar containing antibiotic gradient (Bryson & Szybalski, 1952). Gradients
were prepared in 9 x 9 cm square Petri dishes, with the following concentrations (mg/1):
ceftriaxone 0-0-64, 0-4, 0-64, 0-640; amikacin 0-16, 0-64; pefloxacin 0-2 or 0-32.
Antibiotic concentrations in the gradient vary from 0 to the chosen maxima as a linear
function of the distance from the side of the dish where the gradients starts. After
incubation for 24 h at 37°C, bacterial growth was examined and, when possible, colonies
counted. Typical appearances on these gradients include a confluent growth at lower
antibiotic concentrations and non confluent colonies at higher concentrations. The quite
sharp limit between these two zones has been called the boundary (Brys6n & Szybalsi,
1952). Preliminary comparative studies with our nine bacterial strains indicated that in
the conditions specified above, the antibiotic concentration corresponding to the location
of the boundary was always within two-fold the MIC determined by microdilution
method using an inoculum of 105 cfu/ml and Mueller Hinton broth. We have defined
a significant shift towards resistance when at least one of the two following
criteria was met (i) a greater than two-fold increase of the antibiotic concentration
in the gradient corresponding to the boundary or (ii) greater than ten-fold increase
of the number of colonies growing in the non confluent zone.
Results
One hundred and seventy nine animals were used in this study. At the time of sacrifice,
peritoneal exudates contained 5x10'to 5x10* cfu/ml in the control animals, and always
less in the treated animals (see the last column of Table I). In three instances, a
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Table L Strains used in the study
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Organisms
E. coli 448
K. pneumonia* 24
Ent. cloacae 218
Ent. cloacae 219
Ent. cloacae 895
Ent. cloacae 908*
S. marsescens 240
P. aemginosa 302
Staph. aureus 501
Clinical source
urine
blood culture
CSF
CSF
mediastinum
blood culture
urine
urine
blood culture
Original MICs (mg/1) of:
amikacin
1
2
1
2
1
1
1
8
012
ceftriaxone
< 0 1 2
012
0-25
0-25
0-25
0-25
006
4
0-5
pefloxacin
< 0 1 2
012
012
012
012
0-25
0-25
2
0-25
* Described by Then & Anghern (1982).
contaminant was found in the peritoneum, while in three animals, culture of the
peritoneal exudates yielded no growth. These six animals were excluded from the study.
The treatment resulted in a reduction of the bacterial populations by one to seven logs
(Table II). The cfu decreases were similar for the three antibiotics used as single agents
against all enterobacters, Escherichia 448, Serratia marcescens 240 and Staphylococcus
aureus 501. Pefloxacin was found to be less active than amikacin or ceftriaxone against
Klebsiella pneumoniae 24, but more active against Pseudomonas aeruginosa 302. Com-
binations produced a more potent effect than monotherapy by 10—106 times (Table II).
Exceptions to this general pattern were observed with K. pneumoniae 24, where
morlotherapy by amikacin and ceftriaxone was not improved by combinations. This
may be due to an especially potent effect obtained with the antibiotics alone (lO^lO7
less colonies than in controls), leaving no possibility for improvement with combinations.
Results of Szybalski's gradient were analysed to determine the frequency of resistance
acquired after the different therapeutic regimens. Single-shot treatments allowed easy
selection of resistant mutants in Ent. cloacae, P. aeruginosa, S. marcescens and
K. pneumoniae, but never in mice challenged with E. coli or Staph. aureus (Table II).
Significant shift was most commonly observed after treatment with ceftriaxone, where
five out of the nine strains developed resistance, the four enterobacters and P. aeruginosa
302..- In total, ceftriaxone yielded selection of resistant mutants in 42 of the 57
ceftriaxone-treated mice (74%). When a significant shift occurred after ceftriaxone
therapy the MIC (according to the location of the boundary) increased 128- to 1024-fold
with the enterobacters, and only four-fold with P. aeruginosa 302. In the case of Ent.
cloacae 219, ceftriaxone therapy selected a ceftriaxone-resistant mutant which also
expressed a four-fold reduction in susceptibility to amikacin. In animals treated with
pefloxacin, emergence of mutants with a four- to 16-fold reduction in susceptibility
occurred in 4 strains, K. pneumoniae 24, Ent. cloacae 128, S. marcescens 240 and
P. aeruginosa 302. In this last instance, the mutant resistant to pefloxacin was also resistant
to ceftriaxone. Overall, pefloxacin was responsible for 13 significant shifts among the 23
pefloxacin-treated mice (57%). Four strains, Ent. cloacae 218 and 895, S. marcescens 240
and P. aeruginosa 302, engendered significant shifts on amikacin gradients after therapy.
Significant shifts were not associated with MIC increase but were characterized by a
15-fold increase of the number of colonies growing in the non confluent zone on the
Szybalski's gradient. In the 22 mice treated with amikacin, this aminoglycoside produced
six significant shifts (27%).
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Strains inoculated
into the animal
K. pneumoniae 24
Ent. cloacae 218
Ent. cloacae 219
Ent. cloacae 895
Ent. cloacae 908
S. marcescens 240
P. aeruginosa 302
J . C
Table IIL MIC increases
Treatment given
to the animal
amikacin
ceftriaxone
pefloxacin
amikacin
ceftriaxone
pefloxacin
amikacin
ceftriaxone
pefloxacin
amikacin
ceftriaxone
pefloxacin
amikacin
ceftriaxone
pefloxacin
amikacin
ceftriaxone
pefloxacin
amikacin
ceftriaxone
pefloxacin
Pecbire et al
after passage in treated animals
Fold increase of MIC in treated
animals
amikacin
1
2
1
1
2
1
2
2
1
as compared to controls
with
ceftriaxone pefloxacin
12
102'
102'
5K
1
L
i
\
\
I
I
I K
1
4
\
\
5
16 16
No MIC increases were observed with E. coli 448 and Staph. aweus 501.
In all cases, combinations selected less resistant mutants than the components of the
regimens used alone. In 21 animals, amikacin plus ceftriaxone produced only one shift
on the amikacin gradient (5%) and four shifts on the ceftriaxone gradient (19%). In the
17 mice treated with amikacin and pefloxacin, one (6 %) and four (23 %) shifts respectively
were found on the gradients prepared with amikacin and pefloxacin. Finally, in 21
animals given the combination ceftriaxone-pefloxacin, one shift appeared on the
ceftriaxone gradient (5%) and three others on the pefloxacin gradient (14%). However,
according to the magnitude of the 'boundary' shift on the gradients, the antibiotic
concentrations required for inhibiting the resistant mutants selected by combinations
were similar to those determined in the case of selection by single agents. It never
happened that a combination yielded a significant shift when the agents of the
combination did not. In that sense, no antagonism occurred.
Discussion
Development of resistance during single-drug therapy with ceftriaxone, amikacin and
pefloxacin in the experimental model used in this study is quite similar to that reported
in previous in-vitro studies (Sanders et al., 1984). To some extent, this also corresponds
to clinical experience. In the case of amikacin, emergence of resistance during mono-
therapy is not clearly documented, probably because this agent is usually used in
combination. In contrast, during recent years, emphasis has been laid on the ability of
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certain Gram-negative bacilli to develop resistance rapidly to many of the newer ^ -lactam
antibiotics. The phenomenon was first stressed for cefamandole (Sanders et al., 1982),
but today, the list of compounds for which similar disadvantage has been reported
include nearly all the recently-developed 'enzyme stable' /?-lactams. The bacteria that
possess the ability to become rapidly resistant to these antibiotics during therapy include
such genera as Enterobacter, Pseudomonas, Serratia, Citrobacter and Acinetobacter.
With the newer quinolones, similar problems seem to exist, even though, due to the
lack of sufficient clinical experience, resistance developing during therapy with these
drugs is not so well documented as in the case of /?-lactam antibiotics, but it was well
known with older structurally-related drugs. Many early studies with nalidixic acid and
later with oxolinic acid describe treatment failures associated with selection of resistant
mutants. Accumulated results from 5 trials of nalidixic acid (Slack, 1984) showed 132
failures out of 348 completed courses; of this 39% failure rate, 12% of patients had a
resistant organism of the same species as the initial sensitive one. Also it has been said
that 7% of patients treated with 4 g/day of nalidixic acid will develop resistant organisms
in the urinary tract (Stamey, 1980). However in-vitro selection of resistant mutants during
therapy appears less frequent with the newer fluoroquinolones than with the parent
compounds (Sanders et al., 1984). In addition, due to the improved antibacterial activity
of drugs such as pcfloxacin and ciprofloxacin, the resistant variants, although less
sensitive than the parent strains, might still be regarded as sensitive to these drugs (King,
Shannon & Phillips, 1984). Unfortunately, preliminary clinical experience indicates that
selection of resistant clones during therapy with fluoroquinolones exists. In 28 patients
treated with intravenous ciprofloxacin, the susceptibility of the pathogen decreased
rapidly by several hundred-fold in three instances (Heifer, R., Auckenthaler & Waldvogel,
personal communication). Very interestingly, the bacteria that developed such resistance
belonged to genera already involved in the resistance to newer y?-lactams: P. aeruginosa
and S. marcescens. Ginical experience also teaches that monotherapy can select mutants
showing resistance not only to the drug administered to the patient, but also to other
antibiotics belonging to unrelated classes. In their clinical study on moxalactam for
instance, Preheim et al. (1982) reported the emergence of two strains of P. aeruginosa
with reduced susceptibility to both /Mactams and aminoglycosides.
In contrast to the overwhelming data concerning monotherapy, emergence of resistance
with combinations is much more rarely mentioned in the literature. Examples exist
however, as in the bacteraemia caused by a strain of S. marcescens which gave rise to
mutants resistant to the two antibiotics given to patient, cefotaxime and amikacin
reported by Goldstein et al. (1983). The relative scarcity of reports dealing with similar
experiences contrasts with the great number of infected patients receiving two antibiotics,
but fits with the results of this study, indicating that combinations notably reduce the
risk of resistance emerging during therapy.
The lesser risk of resistance observed with combinations is probably associated with
relative frequencies of resistant variants in bacterial populations before exposure to the
antibiotics, as seen on the Szybalski's gradient. In this study, analysis of the gradient
plated with wild-type bacteria allowed to some extent a forecast of further occurrence
of resistance in the treated mice. More colonies growing on areas corresponding to higher
antibiotic concentrations were more likely to produce a significant shift after passage in
mice treated with the same drug. The mutational frequencies for resistance to a single
antibiotic ranged from 10~* to 10~e in the wild bacteria but the probability of selection
of mutants able to resist simultaneously two structurally unrelated antibiotics was
certainly lower. Actually such cross-resistance was found only once in this study
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contrasting with the ease of obtaining resistance to only one agent. The mechanisms
producing cross resistances between quinolones, aminoglycosides and /Mactams remain
hypothetical, but often multiple drug resistance involves a permeability change, as shown
previously in S. marcescens (Gutmann & Chabbert, 1984), P. aeruginosa (Rella & Hass,
1982), K. pneumoniae (Sanders et al., 1984, Gutmann et al., 1985), and Ent. cloacae
(Gutmann et al., 1985).
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